← All diseases
Heart and blood vessels
Cardiac amyloidosis
Would you like to receive a message when there is new research about cardiac amyloidosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was investigated — and you'll receive a notification as soon as new research on Cardiac Amyloidosis is available. View what Premium costs.
Publications (1059)
- Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis. (2021/07/01) ♡
- Incidence, Cause of Death, and Survival of Amyloidosis in Korea: A Retrospective Population-Based Study. (2021/06/28) ♡
- Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. (2021/06/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Recipe for Success in Transthyretin Cardiomyopathy: Monoclonal Protein Rule Out, SPECT Imaging, and Genetic Testing. (2021/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. New treatment for myocardial diseases. (2021/06/01) ♡
- Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. (2021/06/01) ♡
- Apolipoprotein AI amyloid deposits in the ligamentum flavum in patients with lumbar spinal canal stenosis. (2021/06/01) ♡
- Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. (2021/06/01) ♡
- Cardiac transthyretin amyloidosis (99m)Tc-DPD SPECT correlates with strain echocardiography and biomarkers. (2021/06/01) ♡
- Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype. (2021/06/01) ♡
- Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis. (2021/06/01) ♡
- Cerebrovascular insufficiency and amyloidogenic signaling in Ossabaw swine with cardiometabolic heart failure. (2021/05/24) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Preclinical diagnosis of wild-type transthyretin amyloid cardiomyopathy in a patient undergoing carpal tunnel release. (2021/05/21) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Increased device thresholds with subsequent improvement status post-systemic therapy in a patient with multiple myeloma. (2021/05/18) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Comparative pathological findings between coronary bare-metal stent implantation and balloon angioplasty over 16 years. (2021/05/17) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Radionuclide Imaging in the Diagnosis of Transthyretin Cardiac Amyloidosis: Different Sensitivity in Early-Onset V30M Mutation? (2021/05/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Reference Ranges, Diagnostic and Prognostic Utility of Native T1 Mapping and Extracellular Volume for Cardiac Amyloidosis: A Meta-Analysis. (2021/05/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Prognostic value of right ventricular function in light-chain cardiac amyloidosis treated with bortezomib. (2021/05/01) ♡
- Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: The ACTUAL study. (2021/04/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cardiac amyloidosis: in search of the ideal diagnostic tool. (2021/04/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Value of SPECT imaging in patients with TTR-amyloid: ratios are not enough. (2021/04/01) ♡
- Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. (2021/04/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment. (2021/04/01) ♡
- Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. (2021/04/01) ♡
- Acute exposure to C60 fullerene damages pulmonary mitochondrial function and mechanics. (2021/04/01) ♡
- Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis. (2021/04/01) ♡
- Impact of Arrhythmias on Hospitalizations in Patients With Cardiac Amyloidosis. (2021/03/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Left Ventricular Mass-To-Strain Ratio Predicts Cardiac Amyloid Subtype. (2021/03/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Coexistence of amyloidosis and light chain deposition disease in the heart. (2021/03/01) ♡
- Should We Expand Cardiac Response Criteria in Patients with Light Chain Cardiac Amyloidosis? (2021/03/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Prediction of Incident Heart Failure in TTR Val122Ile Carriers One Year Ahead of Diagnosis in a Multiethnic Biobank. (2021/03/01) ♡
- Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. (2021/03/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Treatment Response Evaluation of Cardiac Amyloidosis Using Serial T1- and T2-Mapping Cardiovascular Magnetic Resonance Imaging. (2021/03/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). (2021/02/15) ♡
- Serum high-density lipoprotein cholesterol serves as a prognostic marker for light-chain cardiac amyloidosis. (2021/02/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. (2021/02/03) ♡
- A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. (2021/02/01) ♡
- Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. (2021/02/01) ♡
- Amyloidosis and cardiovascular diseases: A clinical insight. (2021/02/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. (2021/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Exercise-induced mitral regurgitation and right ventricle to pulmonary circulation uncoupling across the heart failure phenotypes. (2021/02/01) ♡
- Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. (2021/02/01) ♡
- AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. (2021/02/01) ♡
- Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis. (2021/02/01) ♡
- Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. (2021/01/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. (2021/01/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. (2021/01/01) ♡
- [Prognostic factors in light-chain cardiac amyloidosis: a retrospective analysis]. (2021/01/01) ♡
- Tissue Characterization in Cardiology: Moving Beyond Function. (2021/01/01) ♡
- Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly. (2020/12/28) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.